 Connection
Nicholas Cost to Neoadjuvant Therapy
This is a "connection" page, showing publications Nicholas Cost has written about Neoadjuvant Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.648 |
|
|
|
-
Cost NG, Krabbe LM, Bagrodia A, Margulis V. The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. Curr Opin Urol. 2013 Sep; 23(5):411-7.
Score: 0.383
-
Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 12; 39(12):832.e9-832.e15.
Score: 0.162
-
Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8.
Score: 0.080
-
Walther A, Cost NG, Garrison AP, Geller JI, Alam S, Tiao GM. Renal rhabdomyosarcoma in a pancake kidney. Urology. 2013 Aug; 82(2):458-60.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|